Contraindicated in:
Use Cautiously in:
Endo: Graves' disease.
F and E: hypophosphatemia.
GI: ↑ liver enzymes, abdominal pain, autoimmune hepatitis, LACTIC ACIDOSIS/HEPATOMEGALY WITH STEATOSIS, POST-TREATMENT ACUTE EXACERBATION OF HEPATITIS B.
GU: ACUTE RENAL FAILURE/FANCONI SYNDROME, renal impairment.
Metab: ↓ weight.
MS: ↓ bone mineral density, bone pain, muscle pain, osteomalacia, polymyositis.
Neuro: Guillain-Barré syndrome, headache.
Misc: immune reconstitution syndrome.
Drug-Drug:
(Generic available)
HIV-1 Infection
Renal Impairment
HIV-1 PrEP
Therapeutic Classification: antiretrovirals
Pharmacologic Classification: nucleoside reverse transcriptase inhibitors
Emtricitabine
Absorption: Rapidly and extensively absorbed (93% bioavailable).
Distribution: Unknown.
Metabolism/Excretion: Undergoes some metabolism with 86% renally excreted and 14% excreted in feces as metabolites.
Half-life: 10 hr.
Tenofovir Disoproxil Fumarate
Absorption: Tenofovir disoproxil fumarate is a prodrug and undergoes hydrolysis to be converted to tenofovir, the active component.
Distribution: Unknown.
Metabolism/Excretion: 7080% excreted unchanged in urine by glomerular filtration and active tubular secretion.
Half-life: 17 hr.
(plasma concentrations)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
Emtricitabine PO | rapid | 12 hr | 24 hr |
Tenofovir PO | rapid | 12 hr | 24 hr |
NDC Code*